Dr. Pestell founded ProstaGene to rapidly bring to cancer patients the benefits of the prostate cancer testing and metastasis technologies discovered under his leadership at the Sidney Kimmel Cancer Center. He is the inventor of record in the ProstaGene patents. He is leading ProstaGene as an active Board Chair, is directly engaged in the recruitment of a fulltime CEO and a Senior Licensing Executive, and will continue to provide Board Chair leadership in the future.
Dr. Pestell, a native of Perth, Western Australia, received his M.B.B.S. from the University of Western Australia, and his M.D. and Ph.D. from the University of Melbourne. He had postdoctoral clinical and research fellowships at the Massachusetts General Hospital and Harvard Medical School; and received his Executive MBA from the Stern School of Business of New York University. From 2005 until January 2015 he was Director of the Sidney Kimmel Cancer Center and an Executive Vice President of Thomas Jefferson University. He previously served as Chairman of the Department of Oncology at the Georgetown School of Medicine and Director of the Lombardi Cancer Center at Georgetown University.
He has authored more than 600 publications and has been published in Cell, Science, Nature Medicine, Molecular Cell and EMBO J. His work has received more than 56,000 citations, his H index 128 and he is currently ranked amongst the top impact researchers in the world for prostate cancer by Google Scholar.
Dr Pestell has served as a consultant and reviewer for funding entities and research agencies and has been an active member of NIH study sections (RO1, SPORES, Cancer Centers, Program projects). He has served on domestic and international advisory boards including the boards of seven NCI Cancer Centers. Dr Pestell has been a reviewer for eighteen distinct scientific journals, has served on editorial boards of 6 journals, and has founded three biotechnology companies.